FDA
-
-
-
-
-
-
-
MeiraGTx to present 3-year data from gene therapy xerostomia study
-
-
-
-
-
-
-
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
-
-
-
-
-
-
-
MeiraGTx Reports First Quarter 2025 Financial and Operational Results
-
-
-
-
-
-
-
MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy
-
-
-
-
-
-
-
MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress
-
-
-
-
-
-
-
MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference
-
-
-
-
-
-
-
MeiraGTx Holdings (MGTX) Announces 4M Share Offering at $7.50/sh, Pursues Multiple Additional Strategic Opportunities
-
322,084 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

